Novo Nordisk and Eli Lilly still have first-mover advantage, but Roche, Pfizer and others all have similar products in the ...

Novo Nordisk is suing to block compounding pharmacies from producing cheaper versions of its medications, Ozempic and Wegovy.

Novo Nordisk NVO has appealed to the U.S. Food and Drug Administration (FDA) to halt the production of compounded versions of ...

Novo Nordisk on Tuesday asked the U.S. Food and Drug Administration to ban compounding pharmacies from making copycat ...

Weight loss can be a challenging journey, especially when seeking effective and accessible solutions. The rise in popularity ...

A new study suggests weight loss drugs like Ozempic and Mounjaro could provide a promising new treatment for substance use ...

FDA recalls thousands of antidepressant bottles due to cancer-causing chemical{beacon} Health Care Health Care   The Big ...

Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own ...

With weight loss injectables like Ozempic and Mounjaro taking the world by storm, the diet industry is seemingly being left ...

The GLP-1 phenomenon is making the fragmentation and dysfunction of the U.S. health care system even more apparent.

Novo Nordisk has requested that the FDA prohibit compounding pharmacies from producing unapproved versions of its popular weight loss and diabetes drugs, Wegovy and Ozempic, CNBC reported Oct. 23. The ...

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.